Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe DOI matches its Crossref record; 88 of the 90 references it cites were found in a registry or an index.
Abstract
Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 has become standard of care for an increasing number of indications (Table 1). Therefore, an increasing number of patients will be exposed to these drugs with a chance of developing toxicities from these treatments. Depending on the immune checkpoint that is targeted, the incidence of toxicity varies. Toxicities from immune checkpoint inhibitors (ICPis) can be divided into infusion reactions and immune-related adverse events (irAEs) or adverse events of special interest (AEoSI).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The occurrence of AI in ICI users has been reported in about 1% of cases and more frequently in individuals receiving combination regimens like anti-CTLA4 plus anti-PD1/PD-L1 agents (4%-8%) (25, 28, 29).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although most international guidelines recommend higher doses of corticosteroids (from 0.5 to 2 mg/kg/day) for other irAEs,5,32,33”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These elements suggest that ICPI-induced thyroid dysfunction may have a pathogenesis similar to spontaneous autoimmune hypothyroidism [16].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“and may be safely administered without compromising outcomes [16,64].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“With ipilimumab (3 mg/kg), the incidence was reported to be between 1% and 5% [1, 2], but higher incidence (up to 10%) has been observed with the higher doses of ipilimumab (10 mg/kg) [4].”
BackgroundInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“6% of patients with a grade 3 or higher AE [14].”
BackgroundNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 10×
“For nivolumab, any treatment-related AE was documented in 74%–85% of patients, with 12%–20% being grade 3 and 4 [2, 6, 7] for metastatic melanoma patients, 58% and 7%, respectively, for advanced cisplatin refractory squamous non-small-cell lung cancer (NSCLC) [8], 69% and 10%, respectively, for metastatic cisplatin re…”
BackgroundInfluentialNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 10×
“For nivolumab, any treatment-related AE was documented in 74%–85% of patients, with 12%–20% being grade 3 and 4 [2, 6, 7] for metastatic melanoma patients, 58% and 7%, respectively, for advanced cisplatin refractory squamous non-small-cell lung cancer (NSCLC) [8], 69% and 10%, respectively, for metastatic cisplatin re…”
BackgroundInfluentialCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 10×
“The reported treatmentrelated AEs for the pembrolizumab-treated groups were 63% and 66% for any AE, and 13% and 16% for grade 3 to 4 toxicities, respectively [13].”
BackgroundInfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 3×
“5–2 times more frequent, in patients receiving anti-PD-1 therapy compared with ipilimumab monotherapy, as reported across several melanoma trials [12].”
BackgroundSelf-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 2×
“19%, respectively, for tyrosine kinase inhibitor refractory metastatic renal cell carcinoma [10].”
BackgroundSelf-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“For nivolumab, any treatment-related AE was documented in 74%–85% of patients, with 12%–20% being grade 3 and 4 [2, 6, 7] for metastatic melanoma patients, 58% and 7%, respectively, for advanced cisplatin refractory squamous non-small-cell lung cancer (NSCLC) [8], 69% and 10%, respectively, for metastatic cisplatin re…”
BackgroundSelf-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 1×
“Diarrhoea and colitis, including severe forms, occur earlier (Figure 2) and are more frequent with combined anti-CTLA4 and anti-PD-1 agents than with either ipilimumab [2, 53, 54] or anti-PD-1 [2].”
BackgroundSelf-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · cited 2×
“In a recent randomised trial that compared nivolumab followed by ipilimumab, or the reverse sequence, in patients with advanced melanoma, a severe AE with the first agent did not predict toxicity with the second one [49].”
BackgroundResultSelf-citationFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · cited 1×
“Diarrhoea and colitis are more frequent with anti-CTLA4 agents than with either nivolumab or pembrolizumab, with grade 3 to 4 AEs occurring in 1%–2% of cases [2, 50].”
BackgroundSelf-citationRibas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572 · cited 1×
“For pembrolizumab, the Keynote-002 study, comparing pembrolizumab at doses of 2 and 10 mg/kg to chemotherapy in ipilimumab pre-treated metastatic melanoma, showed grade 1 to 2 irAEs in 57%–60% and grade 3 to 4 toxicity in 14% of patients [11].”
Self-citationToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318 · cited 3×
“With ipilimumab (3 mg/kg), the incidence was reported to be between 1% and 5% [1, 2], but higher incidence (up to 10%) has been observed with the higher doses of ipilimumab (10 mg/kg) [4].”
BackgroundSelf-citationChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · cited 3×
“Most of the baseline colitisassociated phylotypes were related to Firmicutes (e.g. relatives of Faecalibacterium prausnitzii and Gemmiger formicilis), whereas nocolitis related phylotypes were assigned to Bacteroidetes [46].”
BackgroundSelf-citationPneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215 · cited 3×
“Tapering of steroids should be very slow and careful, over 6 weeks or more; relapses of pneumonitis during steroid tapering have been reported, adding considerations about recurrence in patients who rechallenge immunotherapy [66].”
BackgroundWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · cited 2×
“3 mg/kg ipilimumab, whereas these toxicities increased to 30% with a dose of 10 mg/kg [3].”
BackgroundGettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177 · cited 9×
“Development of vitiligo is predominantly observed in melanoma patients treated with ICPis but not in NSCLC or renal cancer.”
BackgroundInfluentialSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · cited 2×
“Importantly, so far there is no evidence that the clinical outcome of patients on ICPis is affected by the use of immunosuppressive agents for the management of immune-related toxicities [7, 18].”
BackgroundSelf-citationSafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102 · cited 1×
“However, grade 3 or 4 rashes are rare, with an incidence of< 3% with monotherapy ipilimumab or anti-PD-1 and< 5% with the combination [2, 22].”
BackgroundSelf-citationHorvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · cited 5×
“Importantly, so far there is no evidence that the clinical outcome of patients on ICPis is affected by the use of immunosuppressive agents for the management of immune-related toxicities [7, 18].”
BackgroundInfluentialDubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“More specifically, at baseline, an increased presence of bacteria belonging to the Bacteroidetes phylum species was found in patients who remained free of colitis after ipilimumab treatment [45].”
BackgroundHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968 · cited 1×
“Diarrhoea and colitis, including severe forms, occur earlier (Figure 2) and are more frequent with combined anti-CTLA4 and anti-PD-1 agents than with either ipilimumab [2, 53, 54] or anti-PD-1 [2].”
BackgroundSelf-citationManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903 · cited 1×
“Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [55, 70, 71].”
BackgroundSelf-citationManagement of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Self-citationBeck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · cited 2×
“Patients with a history of autoimmune disease, or who are being actively treated for an autoimmune disease, are at risk for worsening of their autoimmune disease while on immune checkpoint blockade [16].”
BackgroundIwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · cited 1×
“Recently, in a murine model, low-level ectopic RNA and protein expression of CTLA4 on thyrotropin and prolactin secreting cells of the pituitary gland [30] was demonstrated.”
BackgroundOsorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · cited 1×
“Recently, a cohort of 51 NSCLC patients treated with pembrolizumab in the Keynote-001 study was prospectively followed by thyroid-stimulating hormone (TSH), triiodothyronine and thyroxine (FT3, FT4) and anti-thyroid antibodies (Abs) measurement [28].”
BackgroundHua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655 · cited 2×
“In a small prospective study, vitiligo was found in up to 25% of patients treated with pembrolizumab [21].”
BackgroundSelf-citationClinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650 · cited 1×
“In one series of patients who were biopsied after developing acute kidney injury while on ICPis an acute tubulo-interstitial nephritis with lymphocytic infiltration was the most frequent finding [79].”
BackgroundCutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649 · cited 1×
“Renal dysfunction is rare with ipilimumab and with anti-PD-1 therapies, occurring in <1% of treated patients [77].”
BackgroundIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · cited 1×
“Two out of six patients with CD or UC had ipilimumab-induced colitis or a relapse of UC or CD [39].”
BackgroundDykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568 · cited 1×
“Two randomised trials have failed to show any benefit from oral administration of budesonide, in an attempt to prevent occurrence of ipilimumab-induced enterocolitis [41, 42].”
BackgroundNeurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 562 · cited 1×
“Vasculitis, polymyositis, myositis and temporal arteritis have also been described [73].”
BackgroundCharacterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418 · cited 14×
“The most frequent skin AEs are rash, pruritus and vitiligo, but the latter is seen mostly in patients treated for melanoma [20].”
BackgroundInfluentialEigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grünwald, V., Kähler, K. C., Loquai, C., Reinmuth, N., Steins, M., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.003 · Cited by 406 · cited 2×
“Liver biopsy may be considered in assisting in the differential diagnosis of more severe hepatitic reactions [15].”
BackgroundManaging Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403 · cited 1×
“Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [55, 70, 71].”
BackgroundAnti–PD-1–Related Pneumonitis during Cancer Immunotherapy
Nishino, M., Sholl, L. M., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505197 · Cited by 373 · cited 3×
“Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [55, 70, 71].”
BackgroundCancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Marthey, L., Mateus, C., Mussini, C., Nachury, M., Nancey, S., Grange, F., Zallot, C., Peyrin-Biroulet, L., Rahier, J. F., Bourdier de Beauregard, M., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv227 · Cited by 340
Self-citationWeber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Slingluff, C. L., Lawrence, D. P., Logan, T. F., Schuchter, L. M., Nair, S., Fecher, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30126-7 · Cited by 334
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278 · cited 1×
“However, several recent case reports have documented the risk of acute allograft rejection after anti-PD-1 therapy [85].”
BackgroundSystematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273 · cited 27×
“Rash is reported in 24% of the patients treated with ipilimumab, in 15% of those receiving anti-PD-1 MoAbs and in 40% with the combination of ipilimumab and nivolumab.”
BackgroundInfluentialIntrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265 · cited 1×
“However, in a dose escalation study, higher serum levels and prolonged administration of anti-CTLA4 Abs resulted in a trend toward a greater incidence of grade 3/4 autoimmune toxicity, but did not seem to increase anticancer response rates [48].”
BackgroundDermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, V., Meyer, N., Lamant, L., Vigarios, E., Mazieres, J., & Delord, J. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000290 · Cited by 265 · cited 1×
“Exacerbation of psoriasis has also been anecdotally reported with these drugs, as well as psoriasiform or lichenoid skin reactions in patients without any history of such skin disease [19, 23].”
BackgroundBerman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J. S., Galbraith, S. M., Targan, S. R., & Wang, H. L. (2010) · PubMed · Cited by 258
Tirumani, S. H., Ramaiya, N. H., Keraliya, A., Bailey, N. D., Ott, P. A., Hodi, F. S., & Nishino, M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0102 · Cited by 254 · cited 1×
“Importantly, radiological features of pneumonitis are not pathognomonic, and can include ground glass opacities, a cryptogenic organising pneumonia-like appearance and interstitial pneumonia pattern [55, 66, 68], as well as characteristics of hypersensitivity pneumonitis.”
BackgroundShi, V. J., Rodic, N., Gettinger, S., Leventhal, J. S., Neckman, J. P., Girardi, M., Bosenberg, M., & Choi, J. N. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.2226 · Cited by 244 · cited 1×
“A lichenoid interface chronic dermatitis is a common finding [25, 26]; • Immunobullous skin lesions akin to dermatitis herpetiformis or bullous pemphigoid; • Keratinocyte alteration—Grover’s disease [27]/acantholytic dyskeratosis; • Immune-reaction mediated by alteration of melanocytes (regression of nevi, prurigo nod…”
BackgroundIpilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235 · cited 1×
“Lobular hepatitis indistinguishable from autoimmune hepatitis is most commonly reported [32, 33]; most cases are panlobular but inflammation may be confined to zone 3.”
BackgroundVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234 · cited 1×
“This preliminary study suggests that vedolizumab is an alternative to infliximab [43].”
BackgroundDiverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C., Diab, A., Hymes, S. R., Duvic, M., Hwu, W., Wargo, J. A., Torres‐Cabala, C. A., et al. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 232 · cited 1×
“Histopathologically, skin reactions may be categorised into four broad groups [24]: • Inflammatory skin disorders, which comprise a range of changes reflecting acute, subacute or chronic inflammation of various patterns, associated with variable epidermal changes, including psoriasiform or lichenoid reactions.”
BackgroundGonzalez, R. S., Salaria, S. N., Bohannon, C. D., Huber, A. R., Feely, M. M., & Shi, C. (2017) · Histopathology · doi:10.1111/his.13118 · Cited by 228 · cited 2×
“A recent pathology study based upon eight cases has described two patterns: active colitis with neutrophilic crypt microabscesses and atrophy as well as crypt epithelial cell apoptosis (n1⁄4 5) or lymphocytic colitis characterised by increased intraepithelial lymphocytes (n1⁄4 3) [51].”
BackgroundIpilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases
Johncilla, M., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000453 · Cited by 208 · cited 1×
“Lobular hepatitis indistinguishable from autoimmune hepatitis is most commonly reported [32, 33]; most cases are panlobular but inflammation may be confined to zone 3.”
BackgroundIpilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 187 · cited 2×
“Exacerbation of psoriasis has also been anecdotally reported with these drugs, as well as psoriasiform or lichenoid skin reactions in patients without any history of such skin disease [19, 23].”
BackgroundHazarika, M., Chuk, M. K., Theoret, M. R., Mushti, S., He, K., Weis, S. L., Putman, A. H., Helms, W. S., Cao, X., Li, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0712 · Cited by 183 · cited 1×
“In the absence of any direct comparison, to date there is no compelling evidence that this incidence might significantly differ between anti-PD-1 and anti-PD-L1 compounds [63].”
BackgroundPulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182 · cited 1×
“Other patterns of lung reaction attributed to immunotherapy are not specific and reflect a range of chronic inflammatory, presumably immune-related processes, giving rise to changes such as non-specific interstitial pneumonitis, sarcoidlike [69] or hypersensitivity pneumonitis-like changes and organising pneumonia pat…”
BackgroundSelf-citationResolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Chmiel, K. D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., & Kefford, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2206 · Cited by 164 · cited 1×
“If there is no response to corticosteroids within 2–3 days, mycophenolate mofetil should be added at 1000 mg twice daily [IV–V, B] [34].”
BackgroundEndocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 150 · cited 1×
“Hypophysitis is very rare in patients treated with anti-PD-1 and anti-PD-L1 [29].”
BackgroundClinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Verschuren, E. C., van den Eertwegh, A. J. M., Wonders, J., Slangen, R. M. E., van Delft, F., Bodegraven, A. A. V., Neefjes‐Borst, A., & de Boer, N. K. H. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.028 · Cited by 147
Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mellati, M., Eaton, K. D., Brooks‐Worrell, B., Hagopian, W., Martins, R. G., Palmer, J. P., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0889 · Cited by 145
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 139 · cited 13×
“Still, little is known about the pathogenesis of thyroid disorders following ICPis.”
BackgroundInfluentialBowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 139
Self-citationThrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 139
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
Eckert, A., Schoeffler, A., Dalle, S., Phan, A., Kiakouama, L., & Thomas, L. (2008) · Dermatology · doi:10.1159/000161122 · Cited by 138
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
Vogel, W. V., Guislain, A., Kvistborg, P., Schumacher, T. N., Haanen, J. B. A. G., & Blank, C. U. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9693 · Cited by 127
Self-citationTetzlaff, M. T., Nagarajan, P., Chon, S. Y., Huen, A., Diab, A. K., Pacha, O., Aung, P. P., Torres-Cabala, C. A., Mays, S. R., Prieto, V. G., et al. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000688 · Cited by 116 · cited 1×
“A lichenoid interface chronic dermatitis is a common finding [25, 26]; • Immunobullous skin lesions akin to dermatitis herpetiformis or bullous pemphigoid; • Keratinocyte alteration—Grover’s disease [27]/acantholytic dyskeratosis; • Immune-reaction mediated by alteration of melanocytes (regression of nevi, prurigo nod…”
BackgroundAcute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
Tadokoro, T., Keshino, E., Makiyama, A., Sasaguri, T., Ohshima, K., Katano, H., & Mohri, M. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003514 · Cited by 111
Renal complications of immune checkpoint blockade
Murakami, N., Motwani, S. S., & Riella, L. V. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.004 · Cited by 104 · cited 1×
“2% of cases developed grade 3 to 4 nephritis [78].”
BackgroundRefractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
Lord, J. D., Hackman, R. C., Moklebust, A., Thompson, J. A., Higano, C. S., Chielens, D., Steinbach, G., & McDonald, G. B. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0839-8 · Cited by 100 · cited 1×
“Enterocolitis may even occur several months after the last dose of ipilimumab [40].”
BackgroundLankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., Tajmir-Riahi, A., Göhl, J., Schuler, G., Neurath, M. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128611 · Cited by 88 · cited 1×
“Recently, a colitis, possibly due to CMV reactivation, has been reported in a patient with medically refractory anti-CTLA4 colitis [44].”
BackgroundAutoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
Palla, A. R., Kennedy, D., Mosharraf, H., & Doll, D. C. (2016) · Case Reports in Oncology · doi:10.1159/000452296 · Cited by 83
Wilgenhof, S., Morlion, V., Seghers, A. C., Four, S. D., Vanderlinden, E., Hanon, S., Vandenbroucke, F., Everaert, H., & Neyns, B. (2012) · PubMed · Cited by 82
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
Helgadóttir, H., Kis, L. L., Ljungman, P. T., Larkin, J., Kefford, R. F., Ascierto, P. A., Hansson, J., & Masucci, G. V. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx177 · Cited by 57
Self-citationInfliximab for IPILIMUMAB-Related Colitis—Letter
Arriola, E., Wheater, M. J., Karydis, I., Thomas, G. J., & Ottensmeier, C. H. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2471 · Cited by 55
Uemura, M. I., Fa’ak, F., Haymaker, C., McQuail, N., Sirmans, E., Hudgens, C. W., Barbara, L., Bernatchez, C., Curry, J. L., Hwu, P., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0157-6 · Cited by 53 · cited 1×
“A lichenoid interface chronic dermatitis is a common finding [25, 26]; • Immunobullous skin lesions akin to dermatitis herpetiformis or bullous pemphigoid; • Keratinocyte alteration—Grover’s disease [27]/acantholytic dyskeratosis; • Immune-reaction mediated by alteration of melanocytes (regression of nevi, prurigo nod…”
BackgroundLarkin, J., Chiarion‐Sileni, V., González, R., Grob, J., Cowey, C. L., Lao, C. D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M. S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31822-6 · Cited by 36
Self-citationHeo, M. H., Kim, H. K., Lee, H., & Ahn, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.011 · Cited by 24 · cited 1×
“Recently, a severe case of antineutrophil cytoplasmic antibodyassociated rapid progressive glomerulonephritis was described in a patient with thymic epithelial carcinoma on pembrolizumab treatment [80].”
BackgroundP315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
Collins, M., Michot, J., Danlos, F. X., Champiat, S., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa, I., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx002.440 · Cited by 13
Self-citationGastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade
Collins, M., Michot, J., Danlos, F., Champiat, S., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa-Hézode, I., et al. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)30956-3 · Cited by 2 · cited 1×
“It depicted four different patterns of GI irAEs induced by anti-PD-1 Abs: acute colitis similar to that induced by anti-CTLA4 Abs, microscopic colitis, upper GI involvement and pseudo-obstruction [52].”
BackgroundSelf-citation
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Self-citation
Metadata
- Authors
- Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Gustave Roussy (FR)
- University of Aberdeen (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Royal Marsden NHS Foundation Trust (GB)
- University Hospital Heidelberg (DE)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 28
- Issue
- Suppl 4
- Pages
- iv119-iv142
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2736166064
- Semantic Scholar
- 194ac2232045256ca3b48d0a698a989707a5fd99
- Cited by
- 2,367
- References
- 90
- Citations by year
- 2026: 98 · 2025: 134 · 2024: 163 · 2023: 278 · 2022: 373 · 2021: 419 · 2020: 427 · 2019: 288 · 2018: 163 · 2017: 19
- FWCI
- 107.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 894 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, immunotherapy toxicity, immune-related adverse events, adverse events of special interest, CTLA-4, PD-1, PD-L1, infusion reactions, monoclonal antibodies, toxicity management, follow-up
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Follow-Up Studies, Humans, Medical Oncology, Neoplasms, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.